Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

Application Number

Filing Date

O1/23/04

Thomas M. Briese

(Use as many sheets as necessary)

of 4

Sheet

First Named Inventor
Thomas M. Briese
Art Unit
1645
Examiner Name
to be assigned
Attorney Docket Number
5199-87

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Include na Initials* No.1 the item (i		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Calza L., Manfredi R., Verucchi G., Chiodo F. "SARS: a new emergency in the world health"	
	(Recenti Prog Med. 94(7-8): 284-294, 2003 (Abstract only)	
	5	Drosten et al., "Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome"	
		N. Engl. J. Med., 348: 1967-1976, 2003	
		Kaiser et al., "Viral aetiology of acute respiratory illness in patients with suspected severe acute respiratory syndrome (SARS) in Swizerland"	
	1	Swiss Med. Wkly. 133: 400-401, 2003	
	5	Ksiazek et al., "A Novel Coronavirus Associated With Severe Acute Respiratory Syndrome"	
	1	N. Engl. J. Med., 348: 1953-1966, 2003	
	{	Kuiken et al., "Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome"	
J		Lancet 362: 263-270, 2003	

Examiner Signature	moder	Date Considered	7-11-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentilatity is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Buesun	te for form 1449/PTO				Complete if Known	
				Application Number	10/764,075	
INF	ORMATION	DIS	CLOSURE	Filing Date	01/23/04	
(Use as many sheets as necessary)			PPLICANT	First Named Inventor	Thomas M. Briese	
			personal	Art Unit	1645	
				Examiner Name	to be assigned	
Sheet	2	of	4	Attorney Docket Number	5199-87	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
MM	5	Lee et al., "A major outbreak of severe acute respiratory syndrome in Hong Kong"	
1	(N. Engl. J. Med., 348: 1995-2005, 2003	
	5	Li G., Chen X. and Xu A. "Profile of specific antibodies to the SARS-associated coronavirus"	
	~	N. Eng. J. Med. 349: 5-6, 2003	
	5	Mazzulli et al., "Severe acute respiratory syndrome-associated coronavirus in lung tissue"	
		Emerg. Infect. Dis. 10: 20-24, 2004	
	5	Peiris et al., "Coronavirus as a possible cause of severe acute respiratory syndrome in Hong Kong"	
	{	Lancet, 361: 1319-1325, 2003	
	5	Poen, et al., "Early diagnosis of SARS coronavirus infection by real time Kf-PCR"	
	5	J. Clin. Virol. 28: 233-238, 2003	

Examiner	\ \ /	Date	A 11 23
Signature	Male	Considered	17-11-00
	1-01/19-01	Considered	/ +/

^{*}EXAMINER: Initial if reference considered, whether or not diation is in conformance with MPEP 609. Draw line through diation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

K Substitute for form 1449/PTO		Complete if Known
	Application Number	10/764,075
INFORMATION DISCLOSURE	Filing Date	01/23/04
STATEMENT BY APPLICANT	First Named Inventor	Thomas M. Briese
(Use as many sheets as necessary)	Art Unit	1645
(eee to many shoots as necessary)	Examiner Name	to be assigned
Sheet 3 of 4	Attorney Docket Number	5199-87

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MM		Poutanen et al., "Identification of severe acute respiratory syndrome in Canada"	
	7	N. Engl. J. Med., 348: 1995-2005, 2003	
	5	Ren et al., "Detection of SARS-CoV RNA in stool samples of SARS patients by nest RT-PCR and its clinical value"	
		Zhongguo YiXue Ke Xue Yuan Xue Bao 25: 368-371, 2003 (Abstract))
		"SARS"	
	>	Weekly Epidemiological Record 78: 81-83, 2003	
	5	WHO Multicentre Collaborative Network for Severe Acute Respiratory Syndrome (SARS) Diagnosis. A multicentre collaboration to investigate the	
d	{	cause of severe acute respiratory syndrome.	
		Lancet 361: 1730-1733, 2003	
· _			

Examiner	w / -	Date	N 11 -
Signature	Modele	Considered	7-11-05
0.3	1000100	Considered	1 11 00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confideratiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Senstitu	te for form 1449/PTO				Complete ii raiowii	`
				Application Number	10/764,075	
INF	ORMATION	DIS	CLOSURE	Filing Date	01/23/04	
STATEMENT BY APPLICANT				First Named Inventor	Thomas M. Briese	
	(Use as many she	ate ne s	occeend	Art Unit	1645	
(and the many should be necessary)				Examiner Name	to be assigned	
Sheet	4	of	4	Attorney Docket Number	5199-87	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	5	WHO Update 31, Coronavirus never before seen in humans is the cause of SARS, April 16, 2003	
	\	WHO Weekly Epidemiological Record, No. 12, March 21, 2003	
MM	5	Wu et al., "Establishment of a fluorescent polymerase chain reaction method for the detection of the SARS-associated coronavirus and	
1	1	its clinical application".	
		Chin. Med. J. 116: 988-990, 2003	
	5	Yam et al., /Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel	
	7	coronavirus".	
		J. Clin. Microbiol. 41: 4521-4524, 2003	
	{	Zhou et al., "Identification/and molecular cloning and sequence analysis of a novel coronavirus from patients with SARS by/RT-PCR".	
		Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 17, 137-139, 2003	

Examiner	10	Date	
Signature	110014		7-11-05
Oignature	10000	Considered	11100

^{**}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chef Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2005. OMB 0651-0031
U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

SATI	Substitute for form 1449/PTO '			a required to respond to a contaction	of Information unless it contains a valid OMB com Complete if Known	roi number.
Guosata	10 10 10 11 14 31 10			Application Number	10/764,075	
INF	ORMATION	DIS	CLOSURE	Filing Date	01/23/2004	_
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Thomas Briese	
	(lica se many che	nate no e	annaseand	Art Unit	1645	
(Use as many sheets as necessary)				Examiner Name	to be assigned	
Sheet	1	of	1	Attorney Docket Number	5199-87	

Examiner	NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of						
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
MM	_ 1	Chin - "On the Preparation and Utilization of Isolated and Purified Oligonucleotides" (March 9th, 2002) (On deposit in the Katherine R. Everett Law Library at UNC)					
-							
_							
		·					

Examiner	1/1	Date	0-13-05
Signature	Modey	Considered	1/1/21/3

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicants to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.